HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • tLNPplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文
HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • tLNPplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (18)
  • Publications (16)
  • References (21)
  • Uncategorized (6)
  • Video (1)

Recent Posts

December 4, 2025

HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting

by PJWCreative
Post placeholder image
November 9, 2025

SITC 2025 Poster: Targeting MDSCs with HF1K16 Unlocks Long-Term Survival in Refractory Recurrent Glioma: an update of NCT05388487

by HighField Bio
Post placeholder image
November 9, 2025

SITC 2025 Poster: First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demontrates Tolerability and Early Clinical Response

by HighField Bio
October 31, 2025

Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 – 9, 2025.

by HighField Bio
Post placeholder image
July 31, 2025

Video 1 Test

by PJWCreative
April 21, 2025

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

by HighField Bio

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
November 9, 2025 in Publications

SITC 2025 Poster: Targeting MDSCs with HF1K16 Unlocks Long-Term Survival in Refractory Recurrent Glioma: an update of NCT05388487

HighField Bio 0 Like Post Comments Off on SITC 2025 Poster: Targeting MDSCs with HF1K16 Unlocks Long-Term Survival in Refractory Recurrent Glioma: an update of NCT05388487

Click here  

Read More
Post placeholder image
November 9, 2025 in Publications

SITC 2025 Poster: First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demontrates Tolerability and Early Clinical Response

HighField Bio 0 Like Post Comments Off on SITC 2025 Poster: First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demontrates Tolerability and Early Clinical Response

Click here  

Read More

Download Company Profile

Home
Platforms
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin

© 2023-25 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc

en_US English
en_US English
zh_CN 简体中文